318 related articles for article (PubMed ID: 25113746)
1. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
2. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
Chen J; Landegger LD; Sun Y; Ren J; Maimon N; Wu L; Ng MR; Chen JW; Zhang N; Zhao Y; Gao X; Fujita T; Roberge S; Huang P; Jain RK; Plotkin SR; Stankovic KM; Xu L
Nat Protoc; 2019 Feb; 14(2):541-555. PubMed ID: 30617350
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of vestibular schwannomas.
Chang LS; Welling DB
Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
[TBL] [Abstract][Full Text] [Related]
4. Reduction of sporadic and neurofibromatosis type 2-associated vestibular schwannoma growth in vitro and in vivo after treatment with the c-Jun N-terminal kinase inhibitor AS602801.
Dougherty MC; Shibata SB; Clark JJ; Canady FJ; Yates CW; Hansen MR
J Neurosurg; 2023 Apr; 138(4):962-971. PubMed ID: 36087315
[TBL] [Abstract][Full Text] [Related]
5. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
6. Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas).
Welling DB
Laryngoscope; 1998 Feb; 108(2):178-89. PubMed ID: 9473065
[TBL] [Abstract][Full Text] [Related]
7. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 2 (NF2): diagnosis and management.
Lloyd SK; Evans DG
Handb Clin Neurol; 2013; 115():957-67. PubMed ID: 23931824
[TBL] [Abstract][Full Text] [Related]
9. Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas.
Ruiz-García C; Lassaletta L; López-Larrubia P; Varela-Nieto I; Murillo-Cuesta S
Hear Res; 2024 Jun; 447():109012. PubMed ID: 38703433
[TBL] [Abstract][Full Text] [Related]
10. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis Type 2: a matched cohort study with sporadic vestibular schwannomas.
Kruyt IJ; Verheul JB; Hanssens PEJ; Kunst HPM
J Neurosurg; 2018 Jan; 128(1):49-59. PubMed ID: 28128697
[TBL] [Abstract][Full Text] [Related]
11. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma.
Irving RM; Moffat DA; Hardy DG; Barton DE; Xuereb JH; Maher ER
Hum Mol Genet; 1994 Feb; 3(2):347-50. PubMed ID: 8004107
[TBL] [Abstract][Full Text] [Related]
12. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas.
Kluwe L; Mautner V; Heinrich B; Dezube R; Jacoby LB; Friedrich RE; MacCollin M
J Med Genet; 2003 Feb; 40(2):109-14. PubMed ID: 12566519
[TBL] [Abstract][Full Text] [Related]
13. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth.
Bonne NX; Vitte J; Chareyre F; Karapetyan G; Khankaldyyan V; Tanaka K; Moats RA; Giovannini M
J Neurooncol; 2016 Aug; 129(1):47-56. PubMed ID: 27177628
[TBL] [Abstract][Full Text] [Related]
14. Surgical treatment of large vestibular schwannomas in patients with neurofibromatosis type 2: outcomes on facial nerve function and hearing preservation.
Zhao F; Wang B; Yang Z; Zhou Q; Li P; Wang X; Zhang J; Zhang J; Liu P
J Neurooncol; 2018 Jun; 138(2):417-424. PubMed ID: 29492767
[TBL] [Abstract][Full Text] [Related]
15. Somatic neurofibromatosis type 2 gene mutations and growth characteristics in vestibular schwannoma.
Irving RM; Harada T; Moffat DA; Hardy DG; Whittaker JL; Xuereb JH; Maher ER
Am J Otol; 1997 Nov; 18(6):754-60. PubMed ID: 9391673
[TBL] [Abstract][Full Text] [Related]
16. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
17. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
18. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis.
Smith MJ; Bowers NL; Bulman M; Gokhale C; Wallace AJ; King AT; Lloyd SK; Rutherford SA; Hammerbeck-Ward CL; Freeman SR; Evans DG
Neurology; 2017 Jan; 88(1):87-92. PubMed ID: 27856782
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Zhao Y; Liu P; Zhang N; Chen J; Landegger LD; Wu L; Zhao F; Zhao Y; Zhang Y; Zhang J; Fujita T; Stemmer-Rachamimov A; Ferraro GB; Liu H; Muzikansky A; Plotkin SR; Stankovic KM; Jain RK; Xu L
Proc Natl Acad Sci U S A; 2018 Feb; 115(9):E2077-E2084. PubMed ID: 29440379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
